BioCentury
ARTICLE | Company News

Araxes Pharma, J&J deal

March 4, 2013 8:00 AM UTC

Araxes partnered with Johnson & Johnson's Janssen Biotech Inc. subsidiary to discover and develop therapeutics against an undisclosed target to treat cancer. Araxes, which is responsible for development through Phase I proof of concept, will receive an undisclosed upfront payment and R&D funding. The newco is also eligible for undisclosed milestones, plus tiered royalties. Janssen is responsible for further development and will have exclusive, worldwide rights to commercialize any products. ...